Breast Cancer Research and Treatment

, Volume 110, Issue 1, pp 183–188 | Cite as

Immunohistochemical and molecular subtypes of breast cancer in Nigeria

  • Clement A. Adebamowo
  • Ayotunde Famooto
  • Temidayo O. Ogundiran
  • Toyin Aniagwu
  • Chibuzor Nkwodimmah
  • Effiong E. Akang


Objective Previous studies suggest that the majority of breast cancer in Africans are hormone receptor negative and thus differ from breast cancer in other populations. We decided to evaluate the hormone receptor status of patients seen in our practice to see if they indeed differ from that of other populations. Methods We prospectively collected and analyzed tumors from consecutive patients presenting to our clinic over an 18 months period from July 2004. During the period, we saw 192 patients without previous histological diagnosis and conducted routine histological and immunohistochemical analysis of their tumors for hormone receptor status. Results Most, 65.1% of tumors were ER+, 54.7% were PR+ and 79.7% were HER2 negative. Majority of the tumors, 77.6% were luminal type A, 2.6% were luminal type B, 15.8% were basal type and the remaining 4.0% (6/152) were HER2+/ER− subtype. We found an association between hormone receptor status and tumor grade but not with stage at presentation. Conclusion We conclude that there is no difference in the pattern of hormone receptors in breast cancer patients of African origin compared to other populations and urge more use of hormone manipulation for management of breast cancer in this population.


Breast cancer ER PR HER2/neu Molecular subtypes Nigeria 


  1. 1.
    Parkin DM, Ferlay J, Hamdi-Cherif M et al (2003) Cancer in Africa: epidemiology and prevention. IARC Press, LyonGoogle Scholar
  2. 2.
    American Cancer Society (2007) Cancer facts & figures 2007. American Cancer Society, AtlantaGoogle Scholar
  3. 3.
    Ihekwaba FN (1992) Breast cancer in Nigerian women. Br J Surg 79:771–775PubMedCrossRefGoogle Scholar
  4. 4.
    Adebamowo CA, Adekunle OO (1999) Case-controlled study of the epidemiological risk factors for breast cancer in Nigeria. Br J Surg 86:665–668PubMedCrossRefGoogle Scholar
  5. 5.
    Anyanwu SN (2000) Breast cancer in eastern Nigeria: a ten year review. West Afr J Med 19:120–125PubMedGoogle Scholar
  6. 6.
    Hassan I, Onukak EE, Mabogunje OA (1992) Breast cancer in Zaria, Nigeria. J R Coll Surg Edinb 37:159–161PubMedGoogle Scholar
  7. 7.
    Otu AA, Ekanem IO, Khalil MI et al (1989) Characterization of breast cancer subgroups in an African population. Br J Surg 76:182–184PubMedCrossRefGoogle Scholar
  8. 8.
    Chiedozi LC (1985) Breast cancer in Nigeria. Cancer 55:653–657PubMedCrossRefGoogle Scholar
  9. 9.
    Elmore JG, Moceri VM, Carter D, Larson EB (1998) Breast carcinoma tumor characteristics in black and white women. Cancer 83:2509–2515PubMedCrossRefGoogle Scholar
  10. 10.
    Middleton LP, Chen V, Perkins GH et al (2003) Histopathology of breast cancer among African-American women. Cancer 97:253–257PubMedCrossRefGoogle Scholar
  11. 11.
    Mbonde MP, Amir H, Mbembati NA et al (1998) Characterisation of benign lesions and carcinomas of the female breast in a sub-Saharan African population. Pathol Res Pract 194:623–629PubMedGoogle Scholar
  12. 12.
    Jones BA, Kasi SV, Curnen MG et al (1997) Severe obesity as an explanatory factor for the black/white difference in stage at diagnosis of breast cancer. Am J Epidemiol 146:394–404PubMedGoogle Scholar
  13. 13.
    Miller BA, Hankey BF, Thomas TL (2002) Impact of sociodemographic factors, hormone receptor status, and tumor grade on ethnic differences in tumor stage and size for breast cancer in US women. Am J Epidemiol 155:534–545PubMedCrossRefGoogle Scholar
  14. 14.
    Gukas ID, Jennings BA, Mandong BM et al (2005) Clinicopathological features and molecular markers of breast cancer in Jos, Nigeria. West Afr J Med 24:209–213PubMedGoogle Scholar
  15. 15.
    Ikpatt OF, Kuopio T, Ndoma-Egba R, Collan Y (2002) Breast cancer in Nigeria and Finland: epidemiological, clinical and histological comparison. Anticancer Res 22:3005–3012PubMedGoogle Scholar
  16. 16.
    Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502PubMedCrossRefGoogle Scholar
  17. 17.
    Burstein HJ (2005) The distinctive nature of Her2 positive breast cancers. N Engl J Med 353:1652–1654PubMedCrossRefGoogle Scholar
  18. 18.
    Murray E (2005) Breast cancer clinic at Groote Schuur Hospital. In: AORTIC Newsletter, Edition 2005, pp 10–11Google Scholar
  19. 19.
    Adebamowo CA, Ogundiran TO, Akang EE, Adams-Campbell LL (2003) ER/PR Status of Nigerian Breast Cancer Patients. In: American Association for Cancer Research Annual Meeting, Edition. AACR, Washington, DC, p 103301Google Scholar
  20. 20.
    Bertheau P, Cazala-Hatern D, Meignin V et al (1998) Variability of stored immunohistochemical reactivity on stored paraffin slides. J Clin Pathol 51:370–374PubMedGoogle Scholar
  21. 21.
    Olapade-Olaopa EO, Mackay HE (1998) Variability of immunohistochemical reactivity on stored paraffin slides. J Clin Pathol 51:943PubMedCrossRefGoogle Scholar
  22. 22.
    Goldstein NS, Ferkowicz M, Odish E et al (2003) Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol 120:86–92PubMedCrossRefGoogle Scholar
  23. 23.
    von Wasielewski R, Mengel M, Nolte M, Werner M (1998) Influence of fixation, antibody clones, and signal amplification on steroid receptor analysis. Breast J 4:22–40CrossRefGoogle Scholar
  24. 24.
    Ogbimi RI, Adebamowo CA (2006) Questionnaire survey of working relationships between nurses and doctors in University Teaching Hospitals in Southern Nigeria. BMC Nursing 5:2PubMedCrossRefGoogle Scholar
  25. 25.
    Cockburn R, Newton PN, Agyarko EK et al (2005) The global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Med 2:e100PubMedCrossRefGoogle Scholar
  26. 26.
    Mann GB, Fahey VD, Feleppa F, Buchanan MR (2005) Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. J Clin Oncol 23:5148–5154PubMedCrossRefGoogle Scholar
  27. 27.
    Nichols HB, Trentham-Dietz A, Love RR et al (2005) Difference in breast cancer risk factors by tumor marker subtypes among premenopausal Vietnamese and Chinese women. Cancer Epidemiol Biomarkers Prev 14:41–47PubMedCrossRefGoogle Scholar
  28. 28.
    Schechter AL, Stern DF, Vaidyanathan L et al (1984) The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312:513–516PubMedCrossRefGoogle Scholar
  29. 29.
    Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182PubMedCrossRefGoogle Scholar
  30. 30.
    Clark GM, McGuire WL (1991) Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 51:944–948PubMedGoogle Scholar
  31. 31.
    Jones BA, Kasl SV, Howe CL et al (2004) African American/white differences in breast carcinoma: p53 alterations and other tumor characteristics. Cancer 101:1293–1301PubMedCrossRefGoogle Scholar
  32. 32.
    Sørlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Clement A. Adebamowo
    • 1
  • Ayotunde Famooto
    • 1
  • Temidayo O. Ogundiran
    • 1
  • Toyin Aniagwu
    • 1
  • Chibuzor Nkwodimmah
    • 1
  • Effiong E. Akang
    • 2
  1. 1.Division of Oncology, Department of Surgery, College of MedicineUniversity of Ibadan, University College HospitalIbadanNigeria
  2. 2.Department of Pathology, College of MedicineUniversity of Ibadan, University College HospitalIbadanNigeria

Personalised recommendations